News
ALVO
4.670
-5.08%
-0.250
Alvotech Earnings Call Highlights Growth and Risks
TipRanks · 8h ago
Alvotech falls on Q3 results
Seeking Alpha · 13h ago
Alvotech Reports Nine-Month 2026 Results and Business Update
TipRanks · 18h ago
Corteva Posts Downbeat Q3 Results, Joins Nvidia, Alvotech And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
Benzinga · 19h ago
Why Tetra Tech Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Benzinga · 22h ago
Alvotech Records Revenue Dip And EBITDA Rise In Q3; Manufacturing Expands In New York And Iceland
NASDAQ · 1d ago
Alvotech (ALVO) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 1d ago
Alvotech reports Q3 revenue $111.6M, consensus $128.4M
TipRanks · 1d ago
Alvotech Q3 EPS $(0.23) Misses $(0.07) Estimate, Sales $111.600M Miss $119.037M Estimate
Benzinga · 1d ago
Alvotech reports Q3 results
Seeking Alpha · 1d ago
Here are the major earnings after the close Wednesday
Seeking Alpha · 1d ago
Alvotech Q3 2026 Earnings Preview
Seeking Alpha · 2d ago
Alvotech Initiated at Buy by Jefferies
Dow Jones · 2d ago
Alvotech Price Target Announced at $9.00/Share by Jefferies
Dow Jones · 2d ago
Jefferies Initiates Coverage On Alvotech with Buy Rating, Announces Price Target of $9
Benzinga · 2d ago
3 Small-Cap Healthcare Stocks with More Than 40% Upside, According to Analysts
TipRanks · 2d ago
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 3d ago
Weekly Report: what happened at ALVO last week (1102-1106)?
Weekly Report · 3d ago
Barclays Sticks to Their Buy Rating for Alvotech (ALVO)
TipRanks · 11/04 08:59
Alvotech: The Market Is Still Pricing The Broken Factory
Seeking Alpha · 11/03 10:16
More
Webull provides a variety of real-time ALVO stock news. You can receive the latest news about Alvotech through multiple platforms. This information may help you make smarter investment decisions.
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.